Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Average Rating of "Hold" by Brokerages

Key Points

• Immunocore Holdings PLC has received an average rating of "Hold" from analysts, with two sell ratings, four hold ratings, and six buy ratings amongst twelve research firms.
• The average 1-year price target for the stock is approximately $56.89, indicating potential upside from its current trading levels.
• In its latest quarterly earnings, Immunocore reported revenues of $130.65 million, which was above the consensus estimate, reflecting a year-over-year growth of 30%.

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR - Get Free Report) has received a consensus rating of "Hold" from the twelve research firms that are covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and six have issued a buy rating on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $56.8889.

A number of equities research analysts recently weighed in on the stock. Wall Street Zen cut shares of Immunocore from a "buy" rating to a "hold" rating in a research report on Saturday, August 9th. Zacks Research lowered Immunocore from a "strong-buy" rating to a "hold" rating in a report on Thursday, September 4th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Immunocore in a research report on Saturday, September 27th. Guggenheim began coverage on Immunocore in a report on Thursday, September 18th. They set a "neutral" rating for the company. Finally, Jefferies Financial Group began coverage on Immunocore in a research note on Monday, August 25th. They set a "buy" rating and a $48.00 price objective on the stock.

Immunocore Price Performance

Shares of IMCR opened at $34.01 on Tuesday. The business's fifty day moving average is $33.67 and its 200 day moving average is $32.34. Immunocore has a 12-month low of $23.15 and a 12-month high of $39.33. The company has a quick ratio of 5.86, a current ratio of 5.89 and a debt-to-equity ratio of 1.01. The stock has a market cap of $1.71 billion, a P/E ratio of -85.03 and a beta of 0.79.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.01. Immunocore had a negative net margin of 5.70% and a negative return on equity of 5.40%. The firm had revenue of $130.65 million for the quarter, compared to the consensus estimate of $122.96 million. During the same quarter in the prior year, the company posted ($0.23) earnings per share. The business's revenue was up 30.0% on a year-over-year basis. Sell-side analysts anticipate that Immunocore will post -0.94 earnings per share for the current fiscal year.

Insider Activity at Immunocore

In other news, insider David M. Berman sold 22,532 shares of the business's stock in a transaction that occurred on Friday, September 12th. The stock was sold at an average price of $35.67, for a total value of $803,716.44. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 10.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Immunocore

Institutional investors and hedge funds have recently modified their holdings of the business. GAMMA Investing LLC boosted its position in Immunocore by 51.6% in the third quarter. GAMMA Investing LLC now owns 914 shares of the company's stock worth $33,000 after purchasing an additional 311 shares during the last quarter. Osaic Holdings Inc. boosted its holdings in shares of Immunocore by 117.4% in the 2nd quarter. Osaic Holdings Inc. now owns 3,148 shares of the company's stock worth $97,000 after buying an additional 1,700 shares during the last quarter. Orion Porfolio Solutions LLC boosted its holdings in shares of Immunocore by 4.5% in the 2nd quarter. Orion Porfolio Solutions LLC now owns 23,965 shares of the company's stock worth $752,000 after buying an additional 1,031 shares during the last quarter. State of Tennessee Department of Treasury bought a new position in Immunocore during the second quarter valued at about $132,000. Finally, Oxford Asset Management LLP purchased a new stake in Immunocore during the second quarter worth about $661,000. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.